i think CRDC shareprice will possibly take a dip along with the entire (bear) market we are in,..it just happens that way. that's o.k. by me... more shares to collect.
the main aspect to me this company is in a sector that has the big boys are in watch mode and if they like what they see its mergers and/or buyouts.
ISRG, and this was covered in the c/c, if the device performs to ISRG standards and/or exceeds them there is a royalty licensing fee that goes to CRDC,..more cash hence making CRDC shareprice via a buyout more valuable. and that is what we shareholders know. what else is being worked out that we are not aware of.
from the transscript;
Once Intuitive completes the evaluation, they will have the option to initiate a joint development program for an 8 millimeter surgical stapling cartridge for use with robotic applications.
If Intuitive elects to move forward with the development, we would receive further funding as well as unit based royalty on commercial sales.
the way i figure it if there is a buyout CRDC shareholders could see a nice pop,...i think, and this is purely speculation, $8- $15 a share where it stands now. if the Gen4 really comes out strong and becomes a game changer ,..$12- $25. i'm hoping Gen$ is such a strong surgical advantage that there is a bidding war.
from the transcript;
We expect to complete the first evaluation cases with the Generation 4 device in the third quarter of calendar 2016 with a selected launch target for the fourth quarter of calendar 2016. By the end of the year, we tend to have an improve supply chain, using the most appropriate technologies. Finally, we expect to announced our product pipeline moving forward into 2017.
and here's another diamond that was mentioned in the transcript;
In December, we were pleased to announce that we signed a national innovative technology contract with Novation, the country’s leading healthcare services company with more than 5,200 health system members, including such prestigious names as VHA, UHC, Children’s Hospital Association and Provista. This three year contract with the MicroCutter XCHANGE 30 complements our commercial efforts by enabling Novation members and affiliates to quickly navigate the purchasing process with a designated contracting pathway within their hospitals and health systems.
sorry to hear about your losses. most pinks, at least 99% are total bs companies with bs ceo's.
that is why i have stayed away from pinks. all they do is scam. i've been mainly playing options,...a much better opportunity with r.o.i. i mainly play the indices and mainly SPY. doing quite well with it.
News 
Market Data 
Discover 
AI
